A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis

NCT02021474 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine Prophylaxis

Interventions

DRUG: AGX-201
DRUG: Subcutaneous placebo (Evan's solution = phenol 0.4%, isotonic sodium chloride).

Sponsor

AgoneX Biopharmaceuticals, Inc.